
Infectious Diseases Specialist, FIDSA, FACP #ClinicalResearchPI #COVID19 #ClostridioidesDifficile #Vaccines #IDTwitter
- Tweets8.8K
- Following6.2K
- Followers740
- Likes53.7K

ALT A figure shows approved intravenous Ξ²-lactam agents available in the United States with activity against selected gram-negative antimicrobial-resistant infections. Columns include Antibiotics (Year Approved by FDA), ESBL-Producing Enterobacterales, Carbapenemase-Producing Enterobacterales, Pseudomonas aeruginosa with Difficult-to-Treat Resistance, and Carbapenem-Resistant Acinetobacter baumannii. The antibiotics listed include Cefolozane-tazobactam, Ceftazidime-avibactam, Meropenem-vaborbactam, Cefepime-zidebactam, and others. Green squares indicate agents with expected in vitro activity, while red squares indicate agents without expected in vitro activity.
































